Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609505 · ClinicalTrials.gov registry record · NA
Telemedicine vs. Face-to-Face Cancer Genetic Counseling
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 130
- Enrollment target
NCT00609505 is a NA study that has completed, run by Duke University. The registered enrollment target is 130 participants.
The verdict
NCT00609505, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
Study Summary
Cancer genetic counseling (CGC) has been found to have "substantial" benefits for individuals with breast cancer and their family members; it has been deemed by multiple organizations as "standard of care" for women with breast cancer and their relatives. Unfortunately, there is a disparity in access to CGC, especially among women who live in rural and underserved areas. In North Carolina, only two cancer genetic counselors practice in rural clinics - each only for a few days per month. Therefore, in an effort to make CGC more widely available in a timely manner, we propose to test provision of counseling through telemedicine (TM), in which a patient and health care provider communicate with each other using videoconferencing. In 4 rural oncology clinics, we will implement low-cost TM and compare satisfaction and cost-effectiveness between groups of women designated to have their CGC session by TM or FTF. We'll use a validated measure to assess satisfaction by a phone survey one week after the CGC appointment; cost-effectiveness will be measured at project's end by calculating length of wait time for appointment and costs of equipment, labor, and mileage. Study hypothesis: TM is as satisfactory as FTF counseling and is a more cost-effective way to provide this beneficial service.
Interventions
- OTHER Telemedicine
- OTHER Face-to-Face
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00609505
The ClinicalTrials.gov registry entry for NCT00609505 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Telemedicine is the first listed.
NCT00609505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00609505 about?
NCT00609505 is a clinical study titled "Telemedicine vs. Face-to-Face Cancer Genetic Counseling". Cancer genetic counseling (CGC) has been found to have "substantial" benefits for individuals with breast cancer and their family members; it has been deemed by multiple organizations as "standard of care" for women with breast cancer and their relatives. Unfortunately, there is a disparity in acces...
What is the current status of trial NCT00609505?
This trial is currently completed. It is a NA study. The enrollment target is 130 participants. The study started on 2008-08. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00609505?
The interventions under investigation include: Telemedicine (OTHER), Face-to-Face (OTHER).
Who is sponsoring clinical trial NCT00609505?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.